CenterWatch Monthly May 2008 Issue
Eli Lilly, Wyeth, Schering-Plough Rated Top Pharma Companies in Europe
Results of the CenterWatch 2008 Survey of Investigative Sites in Europe found Eli Lilly rated the top sponsor to work with. Also rated highly were Wyeth and Schering-Plough. The 2008 survey had more sites in Central and Eastern Europe reporting, and the survey was also extended to Canada. The number of countries reporting increased by 11 to 37. CenterWatch rated a total of 16 large pharmaceutical and biotech companies.
Cardiac Safety Services Back in Rhythm
Cardiac safety monitoring has developed into a sizable industry sector and the growing demand for these services has led to much activity in the space recently. Cardiac safety effects have become a common cause for drug withdrawals and delays in regulatory approval. Many concerns about serious cardiovascular side effects are related to drugs used for non-cardiac indications, such as the arthritis drug Vioxx.
European Biotech Outsourcing on Steep Learning Curve
Demand for contracted services in the European biotech sector is buoyant. As the industry matures and more biotech drug candidates reach clinical development, business opportunities for contract research organizations (CROs) and other service providers are growing.
Eye On: Muscular Dystrophy
There are nine known types of muscular dystrophy, which is a group of genetically based, degenerative diseases characterized by a progressive wasting and weakening of fibers of voluntary muscles. They are classified based on their pattern of inheritance, age of onset, and typical symptoms; together, they affect more than 110,000 people in the United States alone. In each of these forms, there is a defect in one of several proteins involved in linking the muscle fiber component F-actin to the sheath of tissue surrounding the muscle fiber.
To read the full articles for this issue or for more information on these and other breaking stories, please click here.